QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
|
Citation:
|
QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
|
QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
|
Citation:
|
QI Yi-fan, ZHONG Wen-zhao, ZHANG Jia-tao. The Next Level: ADAURA, Adjuvant Osimertinib in Completely Resected EGFR-Mutated Non-Small-Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 19-25. DOI: 10.12019/j.issn.1671-5144.2022.01.005
|
DownLoad: